Cosentyx intravenous — Medica

Initial criteria

• age ≥ 18 years
• objective signs of inflammation defined as either C-reactive protein elevated beyond the upper limit of normal OR sacroiliitis reported on magnetic resonance imaging
• prescribed by or in consultation with a rheumatologist

Reauthorization criteria

• patient established on Cosentyx intravenous or subcutaneous for ≥ 6 months
• When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline OR compared with baseline, patient experienced an improvement in at least one symptom such as decreased pain or stiffness or improvement in function or activities of daily living

Approval duration

initial: 6 months; reauth: 1 year